{
    "nct_id": "NCT06781983",
    "official_title": "A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors",
    "inclusion_criteria": "* Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4\n* Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.\n* Measurable disease according to RECIST 1.1.\n* Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.\n* Adequate organ function and hematological function.\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected brain metastases.\n* Participants with an active infection, Any other infection requiring systemic treatment or latent infection.\n* Participants with clinically significant comorbidity(s).\n* History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.\n* Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.\n* Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.\n* Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.\n* Participants with symptomatic heart failure, Acute coronary syndromes\n* Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.\n* Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.\n* Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.",
    "miscellaneous_criteria": "Main"
}